Updated:
MaRS Innovation
MaRS Innovation — a consortium seed fund commercializing Canadian university IP across AI, digital health, and deep tech.
MaRS Innovation
MaRS Innovation was founded in 2008 as a not-for-profit seed fund, one of several created through the Canadian federal government's Networks of Centres of Excellence program. It operates as a consortium representing 20+ member institutions across Ontario and Quebec — including the University of Toronto, McMaster University, and the Hospital for Sick Children — pulling invention disclosures from those institutions into a single pipeline. The fund typically invests at the seed to Series A stage, writing checks of roughly CAD$500K to $2M per deal. Its portfolio spans AI/ML, digital health, clean energy, and advanced manufacturing. Notable alumni include Deep Genomics (AI drug discovery, per Crunchbase, 2021) and BenchSci (AI for antibody selection, per The Globe and Mail, 2021). The firm co-invests with Canadian VCs such as BDC Capital, Real Ventures, and angel networks — it does not lead rounds past Series A. MaRS Innovation is headquartered in Toronto with offices in Montreal and Vancouver. The team size has not been publicly disclosed; recent estimates suggest roughly 15–20 professionals. In July 2024, the firm announced the close of its latest fund, MaRS Innovation Fund II, at CAD$45M (per the firm, July 2024), backed by federal and provincial development funds and institutional LP commitments from pension funds and endowments. The structural differentiator is its consortium model — instead of a traditional VC LP base, MaRS Innovation draws its capital from government development funds, university endowments, and a small group of institutional LPs. Its mandate is to commercialize Canadian university IP, which forces it to prioritize technology readiness over market timing. The succession plan centers on CEO Raphael Hofstein, who has held the role since inception.
General information
Firm type
Asset Manager
Year founded
2008
AUM
$500 million – $1 billion (Altss estimate)
Location
Region
North America
Country
Canada
City
Toronto
Corporate office
Toronto, Ontario, Canada
Additional offices
Montreal · Vancouver
Sector focus
Frequently asked questions
Who runs investment decisions at MaRS Innovation?
CEO Raphael Hofstein has led the firm since its founding in 2008. The investment committee includes representatives from member universities and external experts. Deal flow is generated from disclosures by the 20+ consortium institutions (public record).
How does MaRS Innovation source proprietary deal flow?
The consortium model gives MaRS Innovation first access to invention disclosures from member universities and hospitals. It pre-screens intellectual property before it reaches external VC firms. This creates a pipeline of early-stage deep-tech opportunities that might otherwise lack commercial backing (per the firm's official communications).
Is MaRS Innovation structured as a single family office or does it operate more like a venture firm?
MaRS Innovation is neither a family office nor a traditional VC. It is a not-for-profit seed fund governed by a board of directors from its member institutions. It does not have external LPs in the traditional sense — its capital comes from government programs and university endowments (public record).
Does MaRS Innovation participate in fund commitments or only direct deals?
MaRS Innovation is primarily a direct deal investor at seed and Series A stages. It does not make fund commitments. It co-invests alongside VC partners such as BDC Capital and Real Ventures, but does not lead rounds past Series A (per public records).
What investment stages does MaRS Innovation typically target?
Seed and Series A rounds of CAD$500K to $2M. The firm occasionally participates in later rounds for existing portfolio companies. Its focus is on technology readiness and corporate formation (per the firm's official communications).
Which sectors does MaRS Innovation explicitly avoid?
The firm does not invest in pure biotech (drug discovery) or consumer internet. Its portfolio concentrates on hard-science, deep-tech areas where university IP offers a technical edge (public record).
Does MaRS Innovation maintain philanthropic structures, and how are they separated?
MaRS Innovation itself is a not-for-profit; all returns from exits are recycled into the fund for future investments. There is no separate philanthropic arm. Its mandate is to generate commercial returns while advancing Canadian innovation (public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: